Fullscale_Intervention Study: Genetic Risk Communication in Coronary Heart Disease and Wearables

Coronary Heart Disease Clinical Trial

Official title:

The Effect of Communicating Genetic Risk of Coronary Heart Disease and Wearable Technologies On Wearable-Device-Measured Behavioral Outcomes in East Asians: Protocol of a Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05789966
• Other study ID #: Fullscale_CHD_RCT
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: June 1, 2026

Study information

• Verified date: March 2023
• Source: The University of Hong Kong
• Contact: Youngwon Kim, Dr
• Phone: (+852)28315252
• Email: youngwon.kim[@]hku.hk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: This study aims to determine the effects of communicating genetic risk for Coronary Heart Disease (CHD) alone or in combination with goal setting and prompts from a wearable device on objectively measured sedentary time (ST) in East Asians. It is hypothesized that this combination will lead to significant favorable changes in objectively ST, and that such changes will be more likely to be sustained over 6-month follow-up. Methods: In a parallel group, randomized controlled trial, a total 414 individuals of East Asians aged over 60years will be allocated into one of three groups: 1 control and 2 intervention groups. Blood samples will be used for estimation of CHD genetic and analysis of metabolic risk markers. Genetic risk for CHD will be estimated based on recently identified 79 SNPs (associated with CHD for East Asians) using an established methodology. Questionnaires and physical measurement will be administered at Before and after the 12-month intervention and at 6-month follow-up. Each group will receive a Fitbit device. Both intervention groups will be given CHD genetic risk estimates along with lifestyle advice but one of them will additionally use Fitbit's step-goal setting and prompt functions. The primary outcome is objectively measured sedentary time. Secondary outcomes include objectively measured MVPA, calories burned, and five intermediate metabolic risk markers (total cholesterol/HDL-C/LDL-C/triglycerides).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 414
• Est. completion date: June 1, 2026
• Est. primary completion date: January 1, 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• East Asian ancestry
• Do not meet the WHO-recommended levels of PA (i.e., =150 minutes/week of moderate-intensity PA, =75 minutes/week of vigorous-intensity PA, or an equivalent combination of the two; determined through the IPAQ-Short Form).

Exclusion Criteria:

• Previously diagnosed with CHD, and/or participation in another exercise-intervention study.

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Fitness Trackers
• Genetic Predisposition to Disease
• Heart Diseases
• Myocardial Ischemia
• Sedentary Time

Intervention

Genetic:
• Genetic Risk Estimate+Health Coaching
The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.

Device:
• Genetic Risk Estimate + Fitbit Functions+Health Coaching
Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'. The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
The University of Hong Kong

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in ST (average, in minutes/day) between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	ST (average, in minutes/day) will be objectively measured by the Fitbit tracker.	Baseline, 12-month post-intervention, 6-month follow-up
Secondary	Changes in five activity indicators (steps, 'sedentary minutes', 'lightly active minutes', calories burn, and sleep time)	steps, sedentary minutes, lightly active minutes, calories burn, and sleep time will be objectively measured by the Fitbit tracker.	Baseline, 12-month post-intervention, 6-month follow-up
Secondary	Changes in four CHD markers (total cholesterol/HDL-C/LDL-C/triglycerides) between baseline and 6-month follow-up	Blood samples will be collected to test the four key markers for CHD	Baseline and 6-month follow-up
Secondary	Changes in hand grip strength between baseline and 6-month follow-up	Hand grip strength (in kilograms) will be measured using the Jamar Hydraulic Hand Dynamometer, which has good reliability and reproducibility.	Baseline and 6-month follow-up
Secondary	Changes in systolic/diastolic blood pressure between baseline and 6-month follow-up	Systolic/diastolic blood pressure will be measured using a digital automatic sphygmomanometer	Baseline and 6-month follow-up
Secondary	Changes in Self-reported Physical Activity between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Fruit and Vegetable Consumption between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Smoking Status between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up
Secondary	Changes in Self-reported Psychological Status between baseline and Immediate post-intervention, between baseline and 12-month post-intervention, and between baseline and 6-month follow-up	This outcome will be assessed using an assessment questionnaire.	Baseline, Immediate post-intervention, 12-month post-intervention, 6-month follow-up